#MRI

I started my clinical trial for BLU-945 last week, and this targeted therapy already looks like it’s hitting the bullseye.

Five years ago, two surgeons partnered to remove the majority of a 71mm primary brain tumor from my medial right parietal lobe.

Those on the margins of society or with life-limiting illnesses and other social determinants offer a wisdom that often goes unrecognized.

It is difficult, if not impossible, to imprint on others the what-it’s-likeness of cancer, in my case, brain cancer.

A diagnosis of benign prostatic hyperplasia could protect against prostate cancer development.

This song’s refrain is what we must cling to—you can only try the best you can.

Recently, we met (virtually) with my neuro-oncologist to hear the results of my recent MRI scan.

‘Abbreviated’ MRI beats 3D mammography in new screening study, but cost and utilization remain big questions.

One positive note about the report is the omission of any discussion of metastasis to the spine.

Adding a second screening method finds more early cancer between mammograms but also leads to more false positives.

This could provide a safer, simpler alternative to the invasive surgical biopsies used to diagnosis liver disease.

In our brain-tumor community, each of us spend countless hours wondering what we will do when we receive news of a “bad scan.”

Many low-risk patients receive high-cost procedures that are not recommended.

Every eight weeks I crawl into the dimly lit coffin and lie still to await my fate.